(Q44344127)

2 December 2017

title

Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis (English)

1 reference

2 December 2017

0 references

Hassan H Salama

1

1 reference

2 December 2017

Oldrich J Kolar

series ordinal

2

1 reference

2 December 2017

Ying C Q Zang

series ordinal

3

1 reference

2 December 2017

Jingwu Zhang

series ordinal

4

1 reference

2 December 2017

language of work or name

1 reference

1 February 2003

1 reference

Multiple Sclerosis Journal

2 December 2017

published in

1 reference

2 December 2017

volume

9

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

28-31

1 reference

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS865OA

Review: cytokines and the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS865OA

Critical Influences of the Cytokine Orchestration on the Outcome of Myelin Antigen‐Specific T‐Cell Autoimmunity in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS865OA

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS865OA

Interleukin-10 prevents experimental allergic encephalomyelitis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS865OA

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS865OA

10.1191/1352458503MS865OA

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference